03 May 2018
Russian pharmaceutical company NovaMedica (investment project of Rusnano), Ministry of Industry and Trade of the Russian Federation and Government of the Kaluga Region have concluded Special Investment Contract (SPIC). Denis Manturov, Minister of the Ministry of Industry and Trade, Anatoly Artamonov, Governor of the Kaluga Region, and Alexander Kuzin, General Director of NovaMedica, signed the contract. Arkady Dvorkovich, Deputy Chairman of the Government of the Russian Federation, and Anatoly Chubais, Chairman of the Executive Board of Managing Company “RUSNANO”, were present during the ceremony. SPIC envisages creation of a greenfield facility for manufacturing of sterile injectable dosage forms in the Kaluga region.
13 March 2018
NovaMedica, a Russian pharmaceutical company and investment project of Rusnano, concluded a special investment contract (SPIC) with the Russian Ministry of Industry and Trade and Kaluga region. The SPIC provides for building from scratch a plant for sterile injectable dosage forms. As part of the project, NovaMedica will invest more than three billion rubles to establish the plant. So far, this is the largest SPIC in the Russian pharmaceutical industry in terms of investments.
12 February 2018
NovaMedica, a Russian pharmaceutical company and the investment project of RUSNANO, has announced the collaboration in the area of knowledge and technology transfer between NovaMedica Innotech, an R&D center, and Evonik, a German company and a leader in the global market of excipients for pharmaceutical industry.
02 February 2018
Syndax Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced a new clinical collaboration with AstraZeneca to evaluate the safety and efficacy of AstraZeneca’s durvalumab.
22 January 2018
Since 2011, Russian policy has favoured local production in eorts to reduce reliance on pharmaceutical imports. Vladimir Putin’s ‘Pharma 2020’ policy pushes for as much 90% of drugs consumed in Russia to be made domestically by 2020. Such policies have led multinationals to tap the market through collaborations with domestic drugmakers. Pfizer, for example, teamed with Russian pharma firm NovaMedica last May to build an aseptic manufacturing plant in.
19 January 2018
Israeli start up OCON Medical is blazing a trail in the field of women's health with a new hormone-free contraceptive device. The company's IUB – intrauterine ball consists of copper pearls that prevent pregnancy locally within the uterus for five years.
28 December 2017
NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the conclusion of the Russian Ministry of Industry and Trade on the compliance of the production site of NovaMedica Innotech R&D center, a subsidiary of NovaMedica, with the Russian Good Manufacturing Practice (GMP) standards.
26 December 2017
NovaMedica, a Russian pharmaceutical company and investment project of RUSNANO, announced that it received the approval of the Inter-Agency Commission for conclusion of Special Investment Contract (SPIC) under the investment project aimed at establishing a pharmaceutical plant for sterile injectable drugs in the Kaluga region.
27 November 2017
A round table on Contract Manufacturing of Pharmaceutical Products was held on November 22, 2017, at Pharmtech & Ingredients 2017, the 19th international exhibition of equipment, raw materials and technologies for pharmaceutical manufacturing. The event moderator was Alexander Kuzin, the General Director at NovaMedica.
23 October 2017
NovaMedica has launched in Moscow its R&D Center for development of new drug products. The Center is going to become attractive R&D site for customized developments and contract manufacturing.
29 July 2021
29 July 2021
28 July 2021
28 July 2021